Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great news. Covid - 19 pandemic is over.
Resident Joe Biden said in a 60 Minutes interview Sunday that the COVID-19 pandemic is a thing of the past.
https://www.npr.org/2022/09/19/1123767437/joe-biden-covid-19-pandemic-over
Nice post, RedShoulder
Seven Bullish AVXL Analysist Price Targets:
6/23/2022 Berenberg Bank
Initiated Coverage Buy $40.00 +322.83%
3/16/2022 HC Wainwright (Ram Selvaraju)
Reiterated Rating Buy $42.00 +276.01%
11/25/2021 BTIG Research (Yun Zhong)
Reiterated Rating Buy $34.00 +79.04%
6/28/2021 Cantor Fitzgerald
Boost Target Overweight $31.00 ? $40.00 +42.05%
6/21/2021 Dawson James
Boost Target Buy $19.00 ? $35.00 +37.09%
6/14/2021 Jonestrading
Reiterated Rating Buy $35.00 +125.81%
2/17/2021 LADENBURG THALMANN
Reiterated Rating Buy $20.00 +51.29%
A-V-X-L - WINNER in the CNS Biotech Space.
Yes. You appear to be attached to the detached market more and more. imo
"But $2049 and $1029, and $100. and $50 means busting up big money short hedge funds. They make money a few different ways. One is being employed by BP to depress pps of companies they want to acquire as consulting fees. This is a Unique Opportunity with Big Money on the table. BP will make it ugly. Sit tight. CTAD is nothing compared to prize that awaits".
Agree 100%. I like Dr. Missling. I know you don't but that's okay. We both like the company.:) Nice post.
It is absolutely crazy that most of us on this board, if not all would benefit from A2-73 if allowed availability. We have waited for over seven years for access to this drug as our conditions worsen. We should all demand that CNS disease is a world wide pandemic.
Tired of waiting for access to this drug. Time to knock down the door. What say you?
Fantastic write up, Mayo. Incredible amount of information here. Many thanks.
AVXL. Best in class biotech company in the CNS space. imo
Nice post, georgejjl Our market appears to be detached.
Price target and rating changes over the past three years:
Initiated – Buy – July 24, 2019 – Price Target $16.00
Update – Buy – July 31, 2019 – Price Target $16.00
Update – Buy – August 7 , 2019 – Price Target $16.00
Update – Buy – September 5, 2019 – Price Target $16.00
Update – Buy – September 17, 2019 – Price Target $16.00
Update – Buy – October 24, 2019 – Price Target $16.00
Update – Buy – December 2, 2019 – Price Target $16.00
Update – Buy – December 4, 2019 – Price Target $16.00
Update – Buy – February 4, 2020 – Price Target $16.00
Update – Buy – February 7, 2020 – Price Target $16.00
Update – Buy – May 8, 2020 – Price Target $16.00
https://dawsonjames.com/wp-content/uploads/2022/08/AVXL.8.9.22-final1.pdf
Anavex Life Sciences 8/9/2022 Page 4 of 5
Update – Buy – May 22, 2020 – Price Target $16.00
Update – Buy – June 16, 2020 – Price Target $16.00
Update – Buy – July 1, 2020 – Price Target $16.00
Update – Buy – October 15, 2020 – Price Target $16.00
Update – Buy – November 6, 2020 – Price Target $16.00
Update – Buy – December 15, 2020 – Price Target $16.00
Price Target Change – Buy – February 19, 2021 – Price Target $16.0 to $19.00
Update – Buy – April 5, 2021 – Price Target $19.00
Update – Buy – April 12, 2021 – Price Target $19.00
Update – Buy – May 19, 2021 – Price Target $19.00
Update – Buy – June 8, 2021 – Price Target $19.00
Price Target Change – Buy – June 21, 2021 – Price Target $35.00
Update – Buy – June 28, 2021 – Price Target $35.00
Update – Buy – October 27, 2021 – Price Target $35.00
Update – Buy – November 24, 2021 – Price Target $35.00
Update – Buy – January 11, 2022 – Price Target $35.00
Update – Buy – February 1, 2022 – Price Target $35.00
Update – Buy – February 4, 2022 – Price Target $35.00
Update – Buy – February 10, 2022 – Price Target $39.00
Update – Buy – June 15, 2022 – Price Target $39.00
Update – Buy – August 2, 2022 – Price Target $39.00
Update – Buy – August 9, 2022 – Price Target $39.00
Dawson James Securities, Inc. (the "Firm") is a member of
Going through some refresher courses of good reminders to share.
First Amendment: Freedom of Speech. This is your god given right of free speech.
https://www.law.cornell.edu/constitution/first_amendment
Never be afraid to talk.
AF's blow horn seems to be the signal for a coordinated attack on all biotech companies. If they ever remove him they will find another person to do the same. imo
I think your spot on, abew4me. Great post.
Okay. What's the percentage of insty ownership now? TIA
Nice find, hnbadger1 . A-V-X-L - 2-73 & 3-71 Winners in the CNS biotech space.
https://www.neurologylive.com/view/synaptic-loss-increases-sigmar1-expression-present-pathology-of-early-alzheimer-disease
Agree 100%. Always good information and intentions by the big Red Shoulder.
Correct me if I'm wrong. Anavex gets drug trial protocol approval from the FDA before starting any of it's drug trials. Correct? Anybody?
Off topic. Cutting edge in joint pain treatment. PRP-Platelet-Rich Plasma (PRP) Injections.
In recent years, doctors have learned that the body has the ability to heal itself. Platelet-rich plasma therapy is a form of regenerative medicine that can harness those abilities and amplify the natural growth factors your body uses to heal tissue.
It's the weekend.
https://www.hss.edu/condition-list_prp-injections.asp#:~:text=The%20use%20of%20platelet-rich%20plasma%20%28PRP%29%2C%20a%20portion,joints%2C%20can%20be%20applied%20to%20various%20musculoskeletal%20problems.
Seven years of outstanding safety profile in AZ, PDD and Rett. Also current drug trial result prove better than the current SOC. A2-73 should be approved now with it's track record and the highly unmet need in the CNS biotech space.
Many people are needlessly dying early not having access to this drug. Also, preventing them from a better quality of life in general. imo
Agree, JWC3. ANAVEX is in position 1. TLD P3 AD in SEPT OR OCT. Patience wins!
Dr. Missling smart to stay quiet due to aggressive shorty every time he speaks. Let A2-73 and A3-71 talk with drug trial results better than the current SOC every time.
According to the Centers for Disease Control and Prevention, about 1 in 3 adults in the United States reported not getting enough rest or sleep every day.
Nearly 40% of adults report falling asleep during the day without meaning to at least once a month. Also, an estimated 50 to 70 million Americans have chronic, or ongoing, sleep disorders.
Just the sleeping disorder market makes 2-73 worth $100 share alone...
https://www.nhlbi.nih.gov/health/sleep-deprivation
BS. Cover your short position.
Just the sleep deprivation market makes 2-73 worth $100 share alone.
https://www.nhlbi.nih.gov/health/sleep-deprivation
Seven years of outstanding safety profile in AZ, PDD and Rett. Also current drug trial result prove better than the current SOC. A2-73 should be approved now with it's track record and the highly unmet need in the CNS space.
Many people are needlessly dying early not having access to this drug. Also, preventing them from a better quality of life in general. imo
Natasha Bedingfield - Unwritten (US Version) (Official Video)
AVXL - Winner in the CNS biotech space via ~ Cancun MX.
I agree with you, longtermbeliever..Buckle up. Here in Cancun MX 4 more days with investors. Nice..
Right, Wolf. I know I'm a little on the light side here. $1249.00 once next AZ, PD results come in. Not adjusted for inflation.:)
imo, My assessment of AVXL is right around $70 per share or $5 billion MC with what we know today with current drug trial results.
TGD just got married a few weeks ago. You think he's thinking about brain disease! Lol. Just kidding. Of course he is. Dealing with brain disease and BP not an easy task.
Anavex Life Sciences to Announce Fiscal 2022 Third Quarter Financial Results on Tuesday August 9, 2022
Anavex Life Sciences Corp.
Webcast and Conference Call To be Held Tuesday August 9, 2022, 4:30 pm ET
NEW YORK, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that it will issue financial results for its fiscal quarter ended June 30, 2022 on Tuesday August 9, 2022.
Management will host a conference call on Tuesday August 9, 2022, at 4:30 pm ET to review financial results and provide an update on the execution of the Company’s growth strategy. Following management’s remarks, there will be a question-and-answer session.
Webcast / Conference Call Information:
The live webcast of the conference call will be available on Anavex’s website at www.anavex.com.
The conference call can be also accessed by dialing +1 929 205 6099 for participants in the U.S. using the reference passcode 911357. A replay of the conference call will also be available on Anavex’s website for up to 30 days.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a clinical trial for Alzheimer’s disease, a Phase 2 proof-of-concept study in Parkinson’s disease dementia and both a Phase 2 and a Phase 3 study in adult patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson’s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson’s disease. ANAVEX®3-71, which targets sigma-1 and muscarinic M1 receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the company on Twitter, Facebook, Instagram and LinkedIn.
https://finance.yahoo.com/news/anavex-life-sciences-announce-fiscal-110000800.html
Right! $75 share plus 5000 shares from the purchasing company. Done deal dude!
Prior to their $40 billion run up in MC do to purchasing us.
We will wake up one morning and be bought out for $75 a share. Then the BP that buys us will immediately run up $20 to $40 billion in MC. Lol. Just our luck.
Nice, plexrec! $42 buy price target. Very cheap price for a cutting edge break through CNS biotech drug company.
I think he was referring to shorty.
Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022.
Viewable for the whole world to see. Everybody is watching. Cutting edge technology in the CNS biotech space. AVXL results are better than the current SOC Alzheimer's and Parkinson's Dementia disease. IMO
BTW who is responsible for holding back the wind?
https://finance.yahoo.com/news/anavex-announces-first-entire-clinical-140000330.html
Viewable for the whole world to see. Everybody is watching. Cutting edge technology in the CNS space. AVXL results are better than the current SOC Alzheimer's and Parkinson's Dementia disease.
Let's open at $75 tomorrow!!
Agree. Also Dr. Zelenco Z-Stack. I beat covid - 19 twice. Zinc, D3 and C also work. Best
If the covid vaccine can be implemented to the public within a year then A2-73 with seven years of proven safe drug trials can be approved. Especially with highly needed unmet drug needs.
Great news. With this news today, wouldn't it allow the Aussies and the EU to approve A2-73 as the application works through the FDA? First to approve is the real winner. TIA
Right, kevli33. I never realized he was like that until not to long ago. He also was a frequent hang out with J. Epstein. Not good.
Bill Gates wants global population reduction. Not one of the good guys.
https://www.bing.com/videos/search?q=bill+gates+and+global+population&docid=608044636322335361&mid=AAF18DC1934C365B9F58AAF18DC1934C365B9F58&view=detail&FORM=VIRE